Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RHOC | P08134 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76292 | 1.00 | F10 (0.61) | F10L3MBTL1MAPTTSHRCCR1 | |
| SCHEMBL76592 | 0.91 | F10 (0.73) | F10L3MBTL1MAPT | |
| SCHEMBL76591 | 0.91 | F10 (0.73) | F10L3MBTL1MAPT | |
| SCHEMBL76106 | 0.91 | F10 (0.73) | F10L3MBTL1MAPT | |
| SCHEMBL76107 | 0.91 | F10 (0.73) | F10L3MBTL1MAPT | |
| SCHEMBL76617 | 0.91 | F10 (0.73) | F10L3MBTL1MAPT | |
| SCHEMBL13725967 | 0.88 | F10 (0.53) | F10L3MBTL1TSHRCCR1CYP2C9 | |
| SCHEMBL77682 | 0.85 | F10 (0.84) | F10MAPTPOLB | |
| SCHEMBL75964 | 0.82 | L3MBTL1 (0.55) | F10L3MBTL1TSHRCCR1CYP2C9 | |
| SCHEMBL75965 | 0.82 | L3MBTL1 (0.55) | F10L3MBTL1TSHRCCR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | claimed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | F10 5/4885L3MBTL1 932/4885MAPT 3896/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | F10 22/4885L3MBTL1 2025/4885MAPT 2660/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | F10 5/4885L3MBTL1 932/4885MAPT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.